Hemay 022

Drug Profile

Hemay 022

Alternative Names: Hemay022

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tianjin Hemay Biotech
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 12 Oct 2017 Tianjin Hemay Pharmaceutical plans a phase I trial for HER-2-positive Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (NCT03308201)
  • 16 Oct 2016 Phase-I clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Combination therapy) in China (PO) (NCT03308201)
  • 14 Oct 2015 Phase-I clinical trials in Breast cancer (Late-stage disease) in China (PO) (NCT02476539)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top